Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

NCT00344786 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor's decision

Conditions

Interventions

Sponsor

Biogen